MASSDEVICE ON CALL — Medtech titan Medtronic (NYSE:MDT) rocked the renal denervation world when it reported earlier this month that it’s bellwether Symplicity clinical trial failed to meet efficacy expectations when compared to a sham control arm.
Renal
Medtronic’s new renal denervation trial examines less-severe hypertension
Renal denervation may help the heart on its own | MassDevice.com On Call
MASSDEVICE ON CALL — Renal denervation, studied primarily in treatment of hypertension, may product benefits to heart health independent of those generated by lowering blood pressure, according to researchers reporting results from a small study.
The clinicians cautioned that the results are very early and need confirmation from a larger study, but were worked up about the findings.
Medtronic touts E.U., Aussie wins for next-gen Symplicity renal denervation components
Take renal stenting off the front lines, researchers say
The highly anticipated results from the CORAL clinical trial wasn’t great news for renal stents, as researchers reported that renal-artery stenting offered "no benefits" over drugs alone in treating patients with atherosclerotic renal-artery stenosis and elevated blood pressure, chronic kidney disease, or both.
Medtronic begins U.S. trial of renal denervation in lower-risk patients
Deflating the hype: Are we setting renal denervation up for disappointment?
Renal denervation is still in its youth, but the limited clinical trials and lack of substantial confirmation hasn’t curbed much of the hype for the technology as a means of treating patients with resistant hypertension.
TCT 2013: Boston Scientific issues updates on Vessix renal denervation studies
TCT 2013: Renal denervation does everything
Renal denervation may have lost some of its hype over the course of the last year, but researchers are still findings new ways to utilize the technology to target new diseases.
Kona Medical raises $10M Series D
Kona Medical said it closed a $10 million Series D round it plans to use to enter the Chinese renal denervation market.
Unlike other renal ablation systems, Kona’s Surround Sound device uses external ultrasound to non-invasively target the nerves leading to and from the kidney.
NxStage debuts 1st dialysis center
NxStage Medical (NSDQ:NXTM) said its NxStage Kidney Care division opened its 1st dialysis center outside of St. Louis after winning Medicare certification from the Missouri Board of Health.